US › Healthcare

Eledon Pharmaceuticals Inc (ELDN)

US · Healthcare · Biotechnology

$2.65-0.75%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-31.6M

EPS

$-0.19

EPS estimate

$-0.19

EPS came in at -0.19 against a street estimate of -0.19 — a beat of 0.0%.

Key statistics

Market cap

$225.1M

Forward P/E

5.4

P/B

6.84

Book value

$0.89

EPS (TTM)

$-0.90

52-week high

$4.60

52-week low

$1.35

50-day MA

$3.51

200-day MA

$2.96

Beta

0.94

Analyst view

Analysts rate Eledon Pharmaceuticals Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $9.00.

Shareholding

Insiders

0.33%

Institutions

62.48%

Largest institutional holders

Fund	Stake
Bvf Inc	7.74%
BlackRock Inc	5.39%
Defilade Capital Management, L.P.	4.34%
Vanguard Capital Management, LLC	4.05%
Ensign Peak Advisors Inc	3.03%
Geode Capital Management, LLC	2.21%
Sphera Funds Management Ltd.	2.18%
Catalio Capital Management, LP	2.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eledon Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.